


McN3716

| | | | |
|--------------------|--|-------|----------|
| Cat. No.: | HY-U00159 | | |
| CAS No.: | 69207-52-9 | | |
| Molecular Formula: | C ₁₈ H ₃₄ O ₃ | | |
| Molecular Weight: | 298.46 | | |
| Target: | Mitochondrial Metabolism | | |
| Pathway: | Metabolic Enzyme/Protease | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor. |
| IC ₅₀ & Target | Carnitine palmitoyltransferase I (CPT-1) ^[1] |
| In Vivo | <p>Inhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, respectively, except for 15-HETE which was unaffected. There is a significant 34% reduction in the level of 6-keto-PGF_{1α}, a byproduct of PGI₂ (prostacyclin) in McN3716-treated rats. Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to vehicle^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

PROTOCOL

| | |
|--------------------------------------|--|
| Animal Administration ^[1] | <p>Rats^[1]</p> <p>Male Sprague Dawley rats are used. The rats receive ad libitum access to standard chow and water. At 15 weeks of age, six rats were subjected to either high-energy, head-focused microwave irradiation or CO₂ asphyxiation. A separate group of 11 rats were implanted with a tail vein catheter (intravenous catheter 24 gauge/0.75 inch) and received either an intravenous injection of vehicle or 10 mg/kg of McN3716. Fifteen minutes after injection, rats were rapidly euthanized by high-energy, head-focused microwave irradiation (13.5 kW for 1.6 seconds) to avert ischemia for accurate quantification of in vivo basal levels of nonenzymatic auto-oxidative PUFA metabolites and enzymatically derived metabolites. Previously, we reported that this method reduced β-oxidation of fatty acid by 23% to 74%. McN3716 (Methyl palmoxirate, MEP) readily crosses the blood–brain barrier with a plasma half-life of 0.6 minute in the rat. The brain was excised and stored at -80°C for lipidomics profiling.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |
|--------------------------------------|--|

REFERENCES

[1]. Chen CT, et al. Inhibiting mitochondrial β -oxidation selectively reduces levels of nonenzymatic oxidative polyunsaturated fatty acid metabolites in the brain. *J Cereb Blood Flow Metab.* 2014 Mar;34(3):376-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA